• How are oncology leaders optimizing care in 2023? (beckershospitalreview.com)
  • This report explores treatment breakthroughs highlighted at ASCO 2023, the biggest oncology event of the year, and provides an analysis on how they will reshape the landscape, along with an analysis of some standout oncology therapeutics in the rapidly expanding Mainland China marketplace. (clarivate.com)
  • On July 31, this year (2023), Servier, which conducted the trial with Taiho Oncology, received approval from the European Commission for Lonsurf in combination with bevacizumab for the treatment of adult patients with mCRC who have received two prior anti-cancer treatment regimens, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. (outsourcing-pharma.com)
  • Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. (businesswire.com)
  • Bavituximab-the lead compound in Peregrine's immuno-oncology development program-is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody. (genengnews.com)
  • Added Robert Iannone, AstraZeneca's head of immuno-oncology, global medicines development: "Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers. (genengnews.com)
  • Over the last decade or so, immuno-oncology has gained a reputation as one of the most exciting areas in medicine. (pharmaceutical-technology.com)
  • Abi Millar looks at underexplored fields in immuno-oncology. (pharmaceutical-technology.com)
  • Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline. (pharmaphorum.com)
  • Rumours that the two companies were in talks over a merger had already emerged last week, as Gilead builds an immuno oncology franchise while sales of its hepatitis C drugs wane. (pharmaphorum.com)
  • At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science.In oncology, hematology, immunology and cardiovascular disease - and one of the most diverse and promising pipelines in the industry - each of our passionate colleagues contribute to innovations that drive meaningful change. (biospace.com)
  • This role supports the portfolio of Hematology/Oncology/Cell Therapy assets. (biospace.com)
  • The Early Development Project Manager (ED PM) is accountable for one or more EDPTs of moderate or high complexity and is highly autonomous in supporting the Hematology/Oncology/Cell Therapy portfolio as part of their day-to-day work. (biospace.com)
  • Amy E. McKee, Office of Hematology and Oncology Products, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, White Oak, MD 20993. (aacrjournals.org)
  • The PRISM drug repurposing resource ( https://depmap.org/repurposing ) is a starting point to develop new oncology therapeutics, and more rarely, for potential direct clinical translation. (nature.com)
  • Oncology researchers reading the review will learn how organoids can impact drug development decisions for targeted agents and immune therapeutics with higher throughput and novel high-content image (HCI) analysis. (businesswire.com)
  • Expanding CN Bio's portfolio, the Oncology Service provides a unique means to explore these relationships in vitro , offering a new approach to accelerate the development of cancer therapeutics. (onenucleus.com)
  • The report provides comprehensive information on the therapeutics under development for Pancreatic Endocrine Tumor, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. (asdreports.com)
  • The report reviews pipeline therapeutics for Pancreatic Endocrine Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. (asdreports.com)
  • The report reviews key players involved in the development of Pancreatic Endocrine Tumor (Oncology) therapeutics and enlists all their major and minor projects. (asdreports.com)
  • The report assesses Pancreatic Endocrine Tumor (Oncology) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. (asdreports.com)
  • The report reviews latest news related to pipeline therapeutics for Pancreatic Endocrine Tumor (Oncology). (asdreports.com)
  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Endocrine Tumor (Oncology). (asdreports.com)
  • Devise corrective measures for pipeline projects by understanding Pancreatic Endocrine Tumor (Oncology) pipeline depth and focus of Indication therapeutics. (asdreports.com)
  • Marwan Fakih is professor of medical oncology and therapeutics research at the City of Hope, Duarte, California, and lead US investigator for the phase 3 Sunlight trial that evaluated this combination. (outsourcing-pharma.com)
  • Forty Seven also has a rival developing CD47-based drugs - Canada's Trillium Therapeutics saw its shares soar ahead of the takeover announcement as it has a CD47-targeting drug in clinical development. (pharmaphorum.com)
  • EDINBURGH, Scotland , July 13, 2020 /PRNewswire/ -- St Andrews -based investment firm Eos Advisory has backed Europe's first oncology drug discovery accelerator, Cumulus Oncology , leading a £1.7 million investment round supported by the Scottish Investment Bank, the investment arm of Scottish Enterprise, Alba Equity, Apollo and Investing Women. (prnewswire.co.uk)
  • Researchers looked at drugs approved by the US Food and Drug Administration (FDA) for genomic indications from 2006 to 2020. (cancertherapyadvisor.com)
  • Daily online exclusives cover late breaking oncology news, safe handling and administration of chemotherapy drugs, side effect management, and new developments in specific cancers. (oncologynurseadvisor.com)
  • There are also patient registries and practice guidelines compiled at the American Society of Clinical Oncology and NIH. (pharmaceuticalcommerce.com)
  • Barrett Hospital and the American Society of Clinical Oncology in Alexandria, Va., to create a model for delivering rural cancer care throughout Montana, the Bozeman Daily Chronicle reported Oct. 27. (beckershospitalreview.com)
  • Pancreatic Endocrine Tumor (Oncology) - Drugs in Development, 2021 provides an overview of the Pancreatic Endocrine Tumor pipeline landscape. (asdreports.com)
  • In the FDA's inaugural Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks with hosts Dr. Sanjeeve Bala and Dr. Abhilasha Nair about this new podcast series. (reachmd.com)
  • Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. (businesswire.com)
  • Ibrutinib continues to demonstrate promise for patients living with B-cell malignancies, and we are pleased that the FDA has recognized its potential for people living with CLL and the del17p mutation," said Peter F. Lebowitz, M.D., Ph.D., Global Oncology Therapeutic Area Head, Janssen. (jnj.com)
  • Immunocompromised patients are often treated prophylactically with triazole anti-fungal drugs, including ITZ, particularly if there is a risk of aspergillosis . (ecancer.org)
  • With an estimated duration of response rate of 90.6% at six months and 66.5% at nine months in the agent's clinical trials, in October 2022, the U.S. Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli™) for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least four previous lines of therapy. (ons.org)
  • CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients. (cancertherapyadvisor.com)
  • Despite advances in oncology care, infections remain a major cause of morbidity and mortality among cancer patients [3-5]. (cdc.gov)
  • Bavituximab is under study in the Phase III SUNRISE trial as a treatment of second-line non-small lung cancer, which compares the compound plus chemotherapy docetaxel against placebo plus docetaxel in patients with second-line non-small cell lung cancer (NSCLC), as well as in several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. (genengnews.com)
  • For patients whose tumors have also undergone molecular testing, such as next-generation sequencing, the selection of potential drugs is further guided by any and all applicable results. (wikipedia.org)
  • As this research continues to develop and evolve, the enhanced use of precision oncology in cancer treatment ultimately aims to improve prognosis and outcomes for patients. (biomedcentral.com)
  • In oncology, it is one of the most frequent complaints of patients with cancer and a peculiar variable that requires treatment. (bvsalud.org)
  • As part of our Drugs to Watch™ program, Clarivate experts use proprietary data sources, landscape and event monitoring, and deep market knowledge to identify key drug developments expected to have a significant impact on patients and markets. (clarivate.com)
  • 1 Our solutions for drug application in oncology are developed to help protecting healthcare workers and patients from contamination with cytostatic agents. (bbraun.com)
  • Timothy Whitten, president and CEO at Taiho Technology Inc, said: "The treatment of advanced colorectal cancer has been a core focus of our work at Taiho Oncology since our inception and with good reason - approximately 22% of patients with colorectal cancer in the U.S. are diagnosed after the cancer has metastasized. (outsourcing-pharma.com)
  • From Taiho Pharmaceutical's initial discovery of Lonsurf to this latest regulatory milestone, we are appreciative of the investigators and patients who helped to contribute to our growing body of knowledge of this important therapeutic through their participation in our clinical development programs," said Fabio Benedetti, MD, global chief medical officer for oncology, Taiho Pharmaceutical Co., Ltd. (outsourcing-pharma.com)
  • O'Day joined from Roche nearly a year ago and has been tasked with rebuilding momentum at Gilead as the pool of patients eligible to receive its hepatitis C drugs such as Sovaldi shrinks. (pharmaphorum.com)
  • The drug is also approved as a maintenance therapy for patients who have responded to a platinum-based chemotherapy. (fool.com)
  • The U.S. Food and Drug Administration (FDA) is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab). (medlineplus.gov)
  • However, while new advances in engineering controls and facility design help to protect workers who mix or compound hazardous drugs, there is not similar protection available for nursing personnel who administer these drugs to patients. (cdc.gov)
  • Moreover, GoZ has trained specialists in oncology, oncology nurses and radio oncologists at the government central hospital in Harare. (who.int)
  • RARITAN, NJ - April 8, 2013 - Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted a third Breakthrough Therapy Designation for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. (jnj.com)
  • Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy Designation is intended to expedite the development and review time for a potential new medicine "to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. (jnj.com)
  • Notably, oncology is the leading therapeutic area, with the highest percentage of new clinical development year-on year compared to other CGT therapy areas, indicating a high level of unmet needs and increased industry investment in the space. (pharmaceutical-technology.com)
  • Access GlobalData's new whitepaper, Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States to gain a better understanding of the developments, challenges and opportunities in CGT including exclusive insights on promising future oncology CGT assets in development. (pharmaceutical-technology.com)
  • Hazardous drugs can include those used for cancer therapy, some antiviral drugs, hormone agents, and bioengineered drugs. (cdc.gov)
  • This increase poses important problems, including a) the lack of available antimicrobial therapy for VRE infections, because most VRE are also resistant to drugs previously used to treat such infections (e.g., aminoglycosides and ampicillin), and b) the possibility that the vancomycin-resistant genes present in VRE can be transferred to other gram-positive microorganisms (e.g. (cdc.gov)
  • Today's acquisition signals even tighter vertical integration between oncology care and the distribution channel. (drugchannels.net)
  • Don't miss out on today's top content on Oncology Nurse Advisor . (oncologynurseadvisor.com)
  • ABP 215 is one of four oncology biosimilars in our pipeline, and today's BLA submission is an important milestone as Amgen seeks to expand our oncology portfolio,' said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. (news-medical.net)
  • Developed from adult stem cells residing in the tumor, the paper describes the establishment of living biobanks of organoids readily available for drug discovery and development research. (businesswire.com)
  • Our research clearly shows how developments in tumor organoids are making progress towards generating predictive tools for translational research to address unmet needs within oncology drug development. (businesswire.com)
  • This drug works by binding to a somatostatin receptor on the tumor, using the radiation to destroy cancer cells. (ahdbonline.com)
  • The report provides a snapshot of the Global Therapeutic Landscape of Pancreatic Endocrine Tumor (Oncology). (asdreports.com)
  • Once the TumorGraft has successfully grown, the tumor is then propagated in a second generation of mice and tested against a panel of cancer drugs and drug combinations to help identify more accurately which treatment regimen is likely to be most effective in a specific patient. (wikipedia.org)
  • In this way, various drugs are tested on a live sample of the actual patient's tumor, rather than on the patient. (wikipedia.org)
  • This reduces the likelihood of treatment with ineffective drugs and their associated side effects, and it increases the likelihood of finding a treatment that will work against the patient's tumor. (wikipedia.org)
  • It focuses on how precision oncology has shaped advances in the impact of non-coding RNAs in epigenetics and cancer, immunotherapy and tumor biology, and the clinical significance of various therapies in a range of cancers. (biomedcentral.com)
  • Ex vivo drug screening refers to the out-of-body assessment of drug efficacy in patient derived vital tumor cells. (biomedcentral.com)
  • Accurate tumor localization during oncology has been made possible by the introduction of cutting-edge technology. (researchandmarkets.com)
  • Tumor targeting developments in radiation oncology have paved the way for individualized care due to the field's continual breakthroughs. (researchandmarkets.com)
  • Predictors of adherence to safe handling practices for antineoplastic drugs: a survey of hospital nurses. (cdc.gov)
  • In honor of these nurses and all who work with hazardous drugs (many of which are used in the treatment of cancer) we are posting this blog on how to safely prepare, administer or otherwise handle these drugs. (cdc.gov)
  • Yet among drug classes oncology treatments hold a unique position: A frightening disease of immense scientific interest, hundreds of pipeline drugs and nearly as many protocols for single and combination treatments, a complex distribution and reimbursement, and-as information service companies tell us-unprecedented opportunities for those with the right data. (pharmaceuticalcommerce.com)
  • Many of us within this field predict the PhysioMimix™ PK system and Oncology Service will be a disruptive technology that will accelerate cancer therapeutic development, reduce the number of failed or wrongly-dismissed drugs, and help to eliminate animals from the drug-development pipeline. (onenucleus.com)
  • The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities. (asdreports.com)
  • It's estimated that more than 25% of the 400 cancer drugs in the pipeline are oral. (oncologybuddies.com)
  • Aside from the drugs already approved, there are several others in the pipeline. (pharmaceutical-technology.com)
  • Amgen and Allergan are collaborating on the development and commercialization of four oncology biosimilars. (news-medical.net)
  • This fellowship will train physicians in aspects of clinical trials methodology and analysis, epidemiology, clinical aspects of medical product development, and regulation to facilitate the movement of drugs, biologics, and devices from the basic bench science to commercialization. (cancer.gov)
  • This fellowship will train physicians in aspects of drug, biologic, or device development and related issues and standards to facilitate movement from basic bench science to commercialization. (cancer.gov)
  • Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. (equities.com)
  • Drug utilization data have long provided critical feedback for pharmaceutical marketing, product lifecycle management, and development of best clinical practices. (pharmaceuticalcommerce.com)
  • Accelerate your oncology molecule development by making the right decisions in early phases to move you swiftly and smoothly through critical milestones. (westpharma.com)
  • SAN DIEGO--( BUSINESS WIRE )-- Crown Bioscience , a JSR Life Sciences company and Contract Research Organization (CRO), has announced the publication of its review paper entitled: Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug Discovery and Development. (businesswire.com)
  • Crown Bioscience is dedicated to increasing the number, variety, and quality of models available for drug development by leveraging its already established reputation in patient models by continuously investing in superior solutions for oncology research providing direction not only on the right candidate or combination to progress, but also the right patient. (businesswire.com)
  • They partner with the Early Development Program Leads (EDPLs) to lead cross-matrix Early Development Program Teams (EDPTs) that are the hub of drug development activities at BMS, shaping and executing the drug development strategies from Candidate Declaration through Phase 2 Proof of Concept. (biospace.com)
  • The Associate Director Early Development Project Manager (ED PM) is a seasoned project manager who is accountable for the cross-functional planning and execution of one or more drug development programs including definition of the operational strategy, management of timelines, cost, quality, and risk assessment and mitigation. (biospace.com)
  • Despite considerable progress in cancer drug development over the past few decades, there remains a chasm between the number of investigational new drug (IND) approvals and commercialised oncology drugs. (ddw-online.com)
  • In the current era of rapid marketing approval for promising new products in oncology, dose finding and optimization for small-molecule oncology drugs occurs throughout the development cycle and into the postmarketing setting. (aacrjournals.org)
  • citation needed] TumorGrafts are also being used as a pre-clinical research tool to improve clinical drug development. (wikipedia.org)
  • The development of numerous oral chemotherapy drugs (OCDs) has led to a new paradigm in cancer treatment. (oncologybuddies.com)
  • This fellowship will train individuals with postdoctoral research experience in aspects of research and review of the medical product development process to facilitate the movement of drugs, biologics, and devices from the bench to the bedside. (cancer.gov)
  • This fellowship will train individuals in aspects of the cancer prevention drug, biologic, or device development processes, including their application to study populations, to facilitate the movement of novel approaches from the bench to the community. (cancer.gov)
  • Laboratory studies have demonstrated that many chemotherapeutic drugs are teratogenic (can interfere with the development of a fetus), often in more than one animal species. (cdc.gov)
  • Lailaa Cajee is an experienced oncology pharmacist with a demonstrated history of working in the medical industry, skilled in antineoplastic drugs and aseptic technique processes. (oncologybuddies.com)
  • Background: Despite growing awareness of the hazards of exposure to antineoplastic drugs (ADs), surveys continue to find incomplete adherence to recommended safe handling guidelines. (cdc.gov)
  • Some classes of drugs are more hazardous than others and, as a group, antineoplastic drugs have been shown in animal studies to be some of the most potent teratogenic agents known, at doses typically used in cancer treatment. (cdc.gov)
  • Cipher will pursue pre-clinical studies leading to Investigational New Drug status with the U.S. Food and Drug Administration, Health Canada and other health authorities. (prnewswire.com)
  • Practices pay a nominal fee for Lynx if they agree to share data with McKesson, which massages the information and sells it to drug manufacturers through a service called Integrated Quality (IQ). (pharmaceuticalcommerce.com)
  • Onmark is the second-largest community oncology GPO, with about 2,800 practices. (drugchannels.net)
  • US Oncology brings about 490 more practices to the GPO. (drugchannels.net)
  • That's good news (for now) for oncology practices that buy-and-bill provider-administered drugs. (drugchannels.net)
  • The 2016 Genentech Oncology Trend Report also provides data from managed care organizations, which reported that 28% of oncology drugs were distributed to practices by retail, mail, and specialty pharmacies. (drugchannels.net)
  • Additional protection is available by using the proper types of PPE and following strict work practices when administering the drugs. (cdc.gov)
  • Loxo Oncology is also eligible to receive $450 million in milestone payments upon larotrectinib regulatory approvals and first-commercial sale events in certain major markets, as well as an additional $200 million in milestones payments upon LOXO-195 regulatory approvals and first-commercial sale events in certain major markets. (biopharminternational.com)
  • Kinase inhibitors particularly have been susceptible to this problem, and among the 31 approved drugs of this class, the approvals of eight have included such PMRs and/or commitments. (aacrjournals.org)
  • Indications with the most approvals included drugs targeting the Philadelphia chromosome (14 approvals), EGFR (12 approvals), HER2 (10 approvals), BRAF V600 (9 approvals), and ALK (8 approvals). (cancertherapyadvisor.com)
  • NIOSH has been updating its list of hazardous drugs every two years based on new FDA drug approvals and new warnings on existing drugs. (cdc.gov)
  • As a companion article, check out The Decline and Fall of Physician Buy-and-Bill For Specialty Drugs , which shows how higher-cost hospital outpatient settings have been crowding out lower-cost physician offices. (drugchannels.net)
  • In recent decades, the vast majority of oncology services have shifted to outpatient settings, such as physician offices, hospital-based outpatient clinics, and nonhospital-based cancer centers. (cdc.gov)
  • Elkton, Md.-based ChristianaCare's Radiation Oncology Center at Union Hospital will close by the end of the year, Cecil Whig reported Oct. 25. (beckershospitalreview.com)
  • He has 6 publications and 2 patents in the fields of oncology, toxicology and immunology. (westpharma.com)
  • Oncology drugs take the information game to a new level because cancer and its treatment are qualitatively and quantitatively different from other diseases. (pharmaceuticalcommerce.com)
  • Now, "IntrinsiQ can capture the entire regimen the patient receives, including oral chemotherapies, how much and how frequently the patient receives each drug and for how long, diagnostic tests performed on that patient, how these tests influence treatment decisions, and what supportive care that patient received. (pharmaceuticalcommerce.com)
  • Advanced Accelerator Applications), a radioactive drug, for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (ahdbonline.com)
  • Tune to this podcast for a discussion on telehealth in oncology with Vincent Rajkumar, MD. As he lends his insights on standardizing treatment pathways in oncology. (healtheconomics.com)
  • Since the approval of imatinib, the first small-molecule kinase inhibitor (KI) approved for an oncology indication, the FDA has approved 30 additional small-molecule KIs for the treatment of cancer. (aacrjournals.org)
  • However, it is necessary to perform more controlled studies, demonstrating the effectiveness of techniques for pain control in oncology and to identify the best management, so an alternative or complement to drug treatment. (bvsalud.org)
  • Take your medication as directed and if in doubt contact your oncology treatment centre or pharmacy. (oncologybuddies.com)
  • In addition to a broad product portfolio, B. Braun partners with oncology departments to implement solutions for enhanced cancer treatment and edication management. (bbraun.com)
  • Rubraca is also currently under review by the Food and Drug Administration as a treatment for recurrent, metastatic castrate-resistant prostate tumors with BRCA mutations. (fool.com)
  • The desire for technologically advanced treatment options is growing, which is driving the market for radiation oncology. (researchandmarkets.com)
  • Reproductive health is one of the most vulnerable end points because many hazardous drugs used for cancer treatment target rapidly dividing cells in the same way teratogens target rapidly dividing embryonic cells. (cdc.gov)
  • In addition, there are numerous new drugs that have been approved for cancer treatment. (cdc.gov)
  • This contributes to the low success rate of oncology medicines in the clinic. (onenucleus.com)
  • Neither drug is approved by FDA, the European Medicines Agency, or any other health authority. (biopharminternational.com)
  • ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on. (news-medical.net)
  • Guidelines will be provided on how best to understand individual components as well as the interactions of those components with your oncology drug properties & sensitivities, giving you an increased chance of getting to market quickly. (westpharma.com)
  • Our review addresses issues regarding potential interactions between NHPs and chemotherapies used in pediatric oncology from a pharmacokinetic and pharmacodynamic perspective. (nih.gov)
  • Stay connected with all of the latest from Drug Discovery News. (drugdiscoverynews.com)
  • Clare has assembled a world-class team and we are enthused by their keen focus, deep sector expertise and drive to consolidate Cumulus's position as Europe's first and most successful oncology drug discovery accelerator. (prnewswire.co.uk)
  • This review paper offers essential insights into why 3D in vitro organoids are key culture systems for selecting successful drug candidates, their differences and advantages over other systems, like 2D cell cultures and 3D spheroids, and their applications in drug discovery. (businesswire.com)
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the commercial launch of its Oncology Service in response to the global need to improve cancer drug discovery approval rates. (onenucleus.com)
  • In doing so, the new Oncology Service aims to support improved oncology drug discovery success rates and facilitate precision medicine using patient cells. (onenucleus.com)
  • There is certainly a concerted move towards replacing the use of animal models in drug discovery, as illustrated by the recent vote in the EU parliament. (onenucleus.com)
  • Oncology drug discovery is a fantastic application of our technology. (onenucleus.com)
  • Referring to treatments that harness the immune system in the fight against cancer, it has grown from a niche and somewhat speculative field into a vibrant area of drug discovery. (pharmaceutical-technology.com)
  • The first filing for this drug is planned in the US in late 2017 or early 2018, with filing in the European Union expected in 2018. (biopharminternational.com)
  • This approach is termed precision oncology. (biomedcentral.com)
  • Precision oncology has made progress in leaps and bounds in recent years and is currently at the heart of revolutionizing cancer research. (biomedcentral.com)
  • We are therefore very proud to present a new cross-journal thematic series focusing on precision oncology. (biomedcentral.com)
  • This cross-journal thematic series of original research and review articles gathers the latest research on precision oncology. (biomedcentral.com)
  • The researchers acknowledged that this study is limited by the fact that they used only PubMed to search for randomized studies associated with each drug and indication. (cancertherapyadvisor.com)
  • A Zitter Health survey of managed care executives reported that 31% of provider-administered infusible oncology therapies were fulfilled by either specialty pharmacies or patient brown bagging. (drugchannels.net)
  • Currently, a handful of US Food and Drug Administration (FDA)-approved therapies for MDS are available, including lenalidomide, the erythroid maturation agent luspatercept, hypomethylating agents such as azacitidine and decitabine, and iron chelators such as deferasirox. (medscape.com)
  • Onmark (South San Francisco, CA), a group purchasing organization within McKesson Specialty Care Solutions, boasts 3,000 member clinics and 4,800 physicians who benefit from Onmark's relationships with 18 manufacturers of about 100 oncology drugs. (pharmaceuticalcommerce.com)
  • This morning, McKesson (NYSE:MCK) announced the acquisition of U.S. Oncology. (drugchannels.net)
  • McKesson also picks up the services and Group Purchasing Organization (GPOs) businesses of US Oncology. (drugchannels.net)
  • Two drug wholesalers-McKesson and AmerisourceBergen (NYSE:ABC)-are simultaneously the largest distributors of specialty drugs as well as the owners of the largest community oncology Group Purchasing Organizations (GPOs). (drugchannels.net)
  • After the US oncology acquisition, McKesson and AmerisourceBergen (NYSE:ABC) will now represent almost 80% of all specialty pharmaceutical distribution, which is the primary channel to market for office or clinic-based physicians. (drugchannels.net)
  • McKesson had previously acquired National Oncology Alliance, a small GPO, in April 2006. (drugchannels.net)
  • There is a lack of survival data for many oncology drugs approved for genomic indications in recent years, according to research published in the European Journal of Cancer . (cancertherapyadvisor.com)
  • The analysis encompassed 53 drugs approved by the FDA for 92 genomic indications. (cancertherapyadvisor.com)
  • Overall, 22 drugs/indications (24%) demonstrated an improvement in OS, and 51 (55%) showed an improvement in PFS. (cancertherapyadvisor.com)
  • There were 34 drugs/indications that showed no improvement in OS, PFS, or overall response rate (ORR). (cancertherapyadvisor.com)
  • However, 15 drugs/indications demonstrated improvements in all 3 endpoints. (cancertherapyadvisor.com)
  • There were 18 drugs/indications that demonstrated an improvement in PFS alone, 2 showing an improvement in OS alone, and 3 showing an improvement in ORR alone. (cancertherapyadvisor.com)
  • Haslam A, Kim MS, Prasad V. Overall survival for oncology drugs approved for genomic indications . (cancertherapyadvisor.com)
  • Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc. (prnewswire.com)
  • TSX:CPH) ("Cipher" or "the Company") today announced it has acquired the assets of Melanovus Oncology Inc. ("Melanovus"), a Hershey ( Pennsylvania )-based life sciences company. (prnewswire.com)
  • After administering the drug, the provider submits a claim for reimbursement for the drug and any other medical services. (drugchannels.net)
  • With both white and brown bagging, the provider neither purchases the drug nor seeks drug reimbursement from a third-party payer. (drugchannels.net)
  • Providers are not permitted to bill the third-party payer for drugs, because the pharmacy receives the reimbursement for the drugs sent to the provider. (drugchannels.net)
  • What's the viability for flat-fee reimbursement in oncology? (healtheconomics.com)
  • The distribution channel for provider-administered oncology drugs is undergoing significant change-notwithstanding the Centers for Medicare & Medicaid Services' (CMS) misguided and controversial Part B Drug Payment Model . (drugchannels.net)
  • Compared to traditional xenograft models, TumorGrafts, have a greater degree of accuracy in predicting clinical effectiveness of oncology drugs and thus can decrease clinical risk for drug developers. (wikipedia.org)
  • The effectiveness of radiation oncology has increased due to the use of diagnostic imaging. (researchandmarkets.com)
  • Crucially, it will also empower drug developers to make confident decisions early with patient-derived models before progressing to in vivo studies, reducing, refining and replacing (the 3 Rs) the use of animals where possible. (businesswire.com)
  • Dr Rajendra Kumari, Executive Director, Integrated Solutions at Crown Bioscience said: "There has been a significant increase in demand in the last five years in generating in vitro and in vivo matched patient models in preclinical oncology research. (businesswire.com)
  • The patient picks up a prescription at a pharmacy and then takes the drug to the provider's office for administration. (drugchannels.net)
  • Magellan Rx Management's 2015 Medical Pharmacy Trend Report , which includes data from 59 health plans, representing 129.7 million covered lives, found that 28% of medical benefit drug volume was distributed to physician offices by specialty pharmacies or patient brown bagging. (drugchannels.net)
  • Drug safety in the home is crucial for the patient but also for family members, caregivers, and pets. (oncologybuddies.com)
  • CN Bio's Oncology Service addresses this gap in research by enabling researchers to create human and animal PK profiles and apply them to 3D tumour models and organoids. (onenucleus.com)
  • The marketplace helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. (healtheconomics.com)
  • Much of oncology practice is guideline- or protocol-driven, but a good deal is based on cancer doctors' experience, journal reports, and information from conferences. (pharmaceuticalcommerce.com)
  • Oncology data come in a wide variety of types, including complied prescriber data, clinical practice data and processed claims. (pharmaceuticalcommerce.com)
  • McKesson's and Onmark's information products include practice-level software, Lynx, and the IQ service for drug companies. (pharmaceuticalcommerce.com)
  • Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions. (cancertherapyadvisor.com)
  • As you will see below, pharmacies-via white and brown bagging-have displaced buy-and-bill distribution channels for about one-quarter of oncology products. (drugchannels.net)
  • Cancer chemotherapy is in evolution from non-specific cytotoxic drugs that damage both tumour and normal cells to more specific agents and immunotherapy approaches. (nature.com)
  • Anticancer uses of non-oncology drugs have occasionally been found, but such discoveries have been serendipitous. (nature.com)
  • In vitro mouse studies have suggested that these drugs might have some anticancer activity, but the evidence in human subjects is mixed," said lead investigator Stephen J. Freedland, MD, Division of Urology, Department of Surgery at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai in Los Angeles, California. (oncologynurseadvisor.com)
  • The main reasons for referrals in May were: cardiovascular (13%), oncology (12%), ophthalmology (9%), orthopaedics (6%) and neurosurgery (5%)2. (who.int)
  • The high prevalence of complementary and alternative medicine use including natural health products (NHPs) in the pediatric oncology population is well established. (nih.gov)
  • Do you know what your cancer drug is up to? (pharmaceuticalcommerce.com)
  • Kalorama Information estimates the worldwide cancer drug market at $54 billion. (pharmaceuticalcommerce.com)
  • He is a well known thought leader on international comparisons of cancer drug pricing. (healtheconomics.com)
  • Growth of the cancer drug has slowed, but an expanded approval could increase future sales. (fool.com)
  • Clovis Oncology ( CLVS ) reported $38.3 million to $39.3 million in preliminary fourth quarter sales of its cancer drug Rubraca. (fool.com)
  • 5. Carlezon, W.A. Jr. & Wise, R.A. Rewarding actions drug to its receptor, but rather by the rats, treatments associated with aversive of phencyclidine and related drugs in nucleus ac- failure of an expected drug injection to states such as severe drug withdrawal cumbens shell and frontal cortex. (lu.se)
  • Return them to your nearest oncology facility or pharmacy so that they can dispose of it correctly. (oncologybuddies.com)
  • Closed system drug transfer devices (CSTDs), which are a type of engineering control, can provide an additional level of protection for both pharmacy and nursing personnel. (cdc.gov)
  • When I.V. lines are primed in the pharmacy or primed with a non-drug solution, the potential for exposure of nursing personnel to these drugs is reduced. (cdc.gov)
  • Furthermore, our experts leverage a variety of proprietary data sources to advise clients on key trends and developments in the oncology space. (clarivate.com)
  • The market for radiation oncology is anticipated to be driven by technical developments that increase the efficacy and safety of treatments. (researchandmarkets.com)
  • On Nov. 14, 2017, Bayer announced that it has entered into an exclusive global collaboration with Loxo Oncology, a US biopharmaceutical company, to develop and commercialize larotrectinib and LOXO-195, investigational anti-cancer drugs. (biopharminternational.com)
  • Clare Wareing , a University of Edinburgh PhD graduate, has experience of working with big Pharma players, biotech companies and clinical research organisations (CROs) over a 20-year career and previously founded Nexus Oncology which was acquired by US-based Ockham in 2012. (prnewswire.co.uk)
  • Harnessing novel technology licensed from the Vanderbilt Institute for Integrative Biosystems Research and Education (VIIBRE), led by Professor John Wikswo, the proprietary PhysioMimix™ PK system exposes 3D tumour models to in vivo -like profiles by periodically changing the drug concentration in the well. (onenucleus.com)
  • The expansion of CN Bio's service offering to support oncology studies amplifies the breadth of solutions we provide into a critical area of research, that hasn't been possible before. (onenucleus.com)
  • A significant body of research shows orthotopic PDX models more reliably recapitulate tumour micro- environment, which is materially important to tumour initiation, growth, invasion, metastasis, and drug response. (ddw-online.com)
  • The Interagency Oncology Task Force Fellowship (IOTF) program trains scientists in research and research-related regulatory review, policies, and regulations to develop a skill set that bridges the two disparate processes. (cancer.gov)
  • Despite the prevention efforts to date, workplace contamination has been well documented by research on a small percentage of antineoplastic, or cancer-killing drugs. (cdc.gov)
  • It reflects a neuroadaptation that is the likelihood of drug-seeking behav- mediated gene transfer as a tool for neuropsychi- .nature the result of a powerful psychological iors, whereas administration of small atric research. (lu.se)
  • Champions has formed partnerships with multiple drug developers, including Teva and Pfizer. (wikipedia.org)
  • Additionally, based on the properties summarised previously, it is proposed that itraconazole may synergise with a range of other drugs to enhance the anti-cancer effect, and some of these possible combinations are presented in the supplementary materials accompanying this paper. (ecancer.org)
  • This timely new reference integrates the latest clinical results and laboratory studies on the resistance of specific cancers to chemotherapeutic drugs-covering drug resistance in lung, breast, ovary, and colon cancer as well as hematological malignancies. (routledge.com)
  • This anti-inflammatory property has turned aspirin into a potential drug for inflammation-related cancers such as colorectal cancer (CRC). (lu.se)
  • See The Decline and Fall of Physician Buy-and-Bill For Specialty Drugs . (drugchannels.net)
  • One well-understood cause for this 'translation gap' in oncology is the types of models typically used in preclinical studies. (ddw-online.com)
  • Published studies have shown that workplace exposures to hazardous drugs can cause both acute and chronic health effects such as skin rashes, adverse reproductive outcomes (including infertility, spontaneous abortions, and congenital malformations), and possibly leukemia and other cancers. (cdc.gov)